Karyopharm Therapeutics Inc. (KPTI)股价已触及52周新低，交易价格为7.58美元，这家生物制药公司正面临严峻的市场环境。根据InvestingPro数据显示，该公司在过去十二个月中现金消耗迅速，自由现金流为负1.276亿美元。目前的价格水平较此前位置大幅下跌，反映了投资者的担忧和更广泛的市场趋势。过去一年，Karyopharm股票经历了显著下跌，一年总回报率为-5 ...

$KPTI insiders have traded $KPTI stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.36 per share a year ago.

Michael Mano, the SVP of $KPTI, sold 2,793 shares of the company on 03-04-2025 for an estimated $17,567. We received data on the trade from a recent SEC filing. This ...

加拿大皇家银行：重申Karyopharm Therapeutics(KPTI.US)评级，由优于大市调整至优于大市评级, 目标价由3.00美元调整至3.00美元。 Karyopharm Therapeutics（KPTI.US ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Good morning. My name is Joelle, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics fourth quarter and full year 2024 ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $11.04 and traded as low as ...

EST Karyopharm (KPTI) trading halted, news pendingDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving ...

Baird lowered the firm’s price target on Karyopharm (KPTI) to $54 from $75 and keeps an Outperform rating on the shares. The firm updated its ...